1. Home
  2. ESLT vs RPRX Comparison

ESLT vs RPRX Comparison

Compare ESLT & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Elbit Systems Ltd.

ESLT

Elbit Systems Ltd.

SELL

Current Price

$722.69

Market Cap

33.8B

Sector

Industrials

ML Signal

SELL

Logo Royalty Pharma plc

RPRX

Royalty Pharma plc

SELL

Current Price

$68.70

Market Cap

28.4B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
ESLT
RPRX
Founded
1966
1996
Country
Israel
United States
Employees
N/A
N/A
Industry
Military/Government/Technical
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
33.8B
28.4B
IPO Year
2002
2020

Fundamental Metrics

Financial Performance
Metric
ESLT
RPRX
Price
$722.69
$68.70
Analyst Decision
Hold
Buy
Analyst Count
6
9
Target Price
★ $841.50
$73.50
AVG Volume (30 Days)
69.3K
★ 3.1M
Earning Date
11-17-2026
11-04-2026
Dividend Yield
0.52%
★ 1.37%
EPS Growth
★ N/A
N/A
EPS
N/A
★ 1.03
Revenue
N/A
★ $2,378,193,000.00
Revenue This Year
$14.64
$49.27
Revenue Next Year
$14.29
$9.11
P/E Ratio
$71.88
★ $66.67
Revenue Growth
N/A
★ 5.06
52 Week Low
$453.00
$37.31
52 Week High
$1,016.06
$70.37

Technical Indicators

Market Signals
Indicator
ESLT
RPRX
Relative Strength Index (RSI) 49.10 65.30
Support Level $650.34 $55.48
Resistance Level $743.83 N/A
Average True Range (ATR) 24.43 1.59
MACD -4.20 -0.06
Stochastic Oscillator 41.59 64.56

Price Performance

Historical Comparison
ESLT
RPRX

About ESLT Elbit Systems Ltd.

Elbit Systems Ltd is a technology company involved in producing a portfolio of systems and products for aircraft, land, and naval applications. The company's products are used for defense, homeland security and commercial flight capabilities. Its systems and solutions may be installed on new platforms or it may perform a comprehensive modernization program to transform a platform. Elbit Systems gives instructions to its customers on the proper maintenance of its products and will provide support team specialists when the customer cannot fix a problem. The company operates in five segments: Aerospace; C4I and Cyber; ISTAR and EW; Land; and ESA. It derives maximum revenue from Land Segment. Geographically, it operates in Israel; North America; Europe; Asia-Pacific; Latin America; and Others.

About RPRX Royalty Pharma plc

Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.

Share on Social Networks: